ras Mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3226-3235

  Garcia Rostan, Ginesa ^a   Zhao, Hongyu ^a   Camp, Robert L ^a   Pollan, Marina ^a   Herrero, Agustin ^a   Pardo, Javier ^a   Wu, Ran ^a   Carcangiu, Maria Luisa ^a   Costa, Jose ^a   Tallini, Giovanni ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DNA SEQUENCE; FOLLICULAR CARCINOMA; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE RAS; PAPILLARY CARCINOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CARCINOMA; TUMOR DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA; FEMALE; GENETICS; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SEQUENCE ANALYSIS; STATISTICAL MODEL; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR;

CARCINOMA, PAPILLARY, FOLLICULAR; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; LOGISTIC MODELS; MALE; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEQUENCE ANALYSIS; THYROID NEOPLASMS;

EID: 0141465066     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.130     Document Type: Article

References (28)

1. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
2. Wright PA, Williams ED, Lemoine NR, et al: Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene 6:471-473, 1991
3. Challeton C, Bounacer A, Du Villard JA, et al: Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene 11:601-603, 1995
4. Suchy B, Waldmann V, Klugbauer S, et al: Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer 77:952-955, 1998
5. Hara H, Fulton N, Yashiro T, et al: N-ras mutation: An independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 116:1010-1016, 1994
6. Rosai J, Carcangiu ML, DeLellis RA: Tumors of the thyroid gland, in Atlas of Tumor Pathology (series 3, fascicle 5). Washington, DC, Armed Forces Institute of Pathology, 1992
7. Garcia-Rostan G, Camp RL, Herrero A, et al: b-catenin dysregulation in thyroid neoplasms: Down-regulation, aberrant nuclear expression and ctnnb1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987-996, 2001
8. Efron B, Tibshirani RJ, An Introduction to the Bootstrap. London, United Kingdom, Chapman & Hall, 1993
9. Carcangiu ML, Zampi G, Rosai J: Poorly differentiated ("insular") thyroid carcinoma: A reinterpretation of Langhans' "wuchernde Struma." Am J Surg Pathol 8:655-668, 1984
10. Capella G, Cronauer-Mitra S, Peinado MA, et al: Frequency and spectrum of mutations at codons 12 and 13 of the C-K-ras gene in human tumors. Environ Health Perspect 93:125-131, 1991
11. Cerottini JP, Caplin S, Saraga E, et al: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 175:198-202, 1998
12. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 90:675-684, 1998
13. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85:692-696, 2001
14. Nelson HH, Christiani DC, Mark EJ, et al: Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 91:2032-2038, 1999
15. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al: Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications. J Clin Oncol 16:2468-2477, 1998
16. Broermann P, Junker K, Brandt BH, et al: Trimodality treatment in stage III nonsmall cell lung carcinoma: Prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 94:2055-2062, 2002
17. Kawesha A, Ghaneh P, Andren-Sandberg A, et al: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89:469-474, 2000
18. Kiyoi H, Naoe T, Nakano Y, et al: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080, 1999
19. Lemoine NR, Mayall ES, Wyllie FS, et al: Activated ras oncogenes in human thyroid cancers. Cancer Res 48:4459-4463, 1988
20. Horie H, Yokogoshi Y, Tsuyuguchi M, et al: Point mutations of ras and Gs alpha subunit genes in thyroid tumors. Jpn J Cancer Res 86:737-742, 1995
21. Pilotti S, Collini P, Mariani L, et al: Insular carcinoma: A distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol 21:1466-1473, 1997
22. Emanuel JR, Damico C, Ahn S, et al: Highly sensitive nonradioactive single strand conformational polymorphism: Detection of Ki-ras mutations. Diagn Mol Pathol 5:260-264, 1996
23. Ezzat S, Zheng L, Kolenda J, et al: Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6:409-416, 1996
24. Solakoglu O, Maierhofer C, Lahr G, et al: Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A 99:2246-2251, 2002
25. Harness JK, McLeod MK, Thompson NW, et al: Deaths due to differentiated thyroid cancer: A 46-year perspective. World J Surg 12:623-629, 1988
26. Manenti G, Pilotti S, Re FC, et al: Selective activation of ras oncogenes in follicular and undifferentiated carcinomas. Eur J Cancer 30:987-993, 1994
27. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
28. Yeung S-C J, Xu G, Pan J, et al: Manumycin enhances the effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650-655, 2000